Clarity Pharmaceuticals (ASX: CU6), a leading radiopharmaceutical company in the clinical stage, reports a significant development in its diagnostic trial, SABRE (NCT05407311), based in the United States. This trial, titled "Copper-64 SAR-BisPSMA in Biochemical Recurrence of prostate cancer," has successfully imaged 50 patients using 64Cu-SAR-Bombesin. SABRE focuses on individuals with PSMA-negative biochemical recurrence (BCR) of prostate cancer after definitive therapy. It constitutes a Phase II Positron Emission Tomography (PET) imaging study, utilizing 64Cu-labeled SAR-Bombesin.
SABRE, an acronym for the trial's full name, is a multi-center, single-arm, non-randomized, and open-label study. The primary objectives include evaluating the safety and tolerability of the product while determining its accuracy in detecting prostate cancer recurrence. Clarity Pharmaceuticals remains dedicated to developing next-generation radiopharmaceuticals that enhance treatment outcomes for both children and adults battling cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
